CBV News

Every story built from at least two public sources

Home / Health

FDA orders a rare optic-nerve warning on every GLP-1 drug, 17 months after Europe did it for semaglutide

The FDA's 9 November safety notice adds NAION to the warnings of all GLP-1 drugs. The trial data is thin: 15 probable events. Europe's regulator reached a similar view for semaglutide in 2025.

Health 4 min read

On 9 November the U.S. Food and Drug Administration told the makers of every GLP-1 receptor agonist to add a “potential increased risk” of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their labels. NAION can cause sudden, painless vision loss in one eye, and the loss may be permanent.

The order covers the whole class, whether the drug is sold for diabetes or weight loss. The numbers behind it are small, and the agency itself calls the risk “potential.” Here is what the FDA’s notice contains and what it leaves open.

What the FDA counted

The FDA notice draws on three kinds of evidence. The first is a meta-analysis of 126 randomized trials with 134,253 patients. It found 10 probable NAION events on GLP-1 drugs and 5 on placebo or other comparators, which works out to 6.4 against 3.8 cases per 100,000 person-years.

The second is a study in the FDA’s Sentinel system of adults with type 2 diabetes. Compared with SGLT-2 inhibitors, the hazard ratio was 1.19 and not statistically significant. Compared with DPP-4 inhibitors it was 1.43, with a confidence interval of 1.02 to 2.01, which does show an increased risk.

The third is published observational research. The FDA says the methodologically rigorous studies generally found increased risk against DPP-4 or SGLT-2 inhibitors, consistent with its own findings.

What is still missing

Fifteen events is a very small base for a class-wide order. The FDA says as much: NAION is rare, and the trial analysis had few events.

The agency also found no mechanism. Animal data did not show how a GLP-1 drug would injure the optic nerve. Reports of side effects are hard to read because the usual NAION risk factors, including diabetes, high blood pressure, sleep apnea, smoking, anemia and kidney disease, are common in the people who take these drugs.

The background rate gives a sense of scale. In adults over 50 in the general population, the FDA cites 2.3 to 10.2 cases per 100,000 per year. Both trial rates, 6.4 and 3.8, fall inside that range, which is part of why the trial signal alone is hard to interpret.

Europe got there first, for one drug

The European Medicines Agency’s safety committee reached a comparable finding on 6 June 2025, but only for semaglutide. The EMA announcement says the committee concluded NAION is a very rare side effect of Ozempic, Rybelsus and Wegovy, meaning it may affect up to 1 in 10,000 users.

The EMA put the excess at about one additional case per 10,000 person-years. Large studies in adults with type 2 diabetes found roughly double the risk compared with non-users. The two agencies used different data, so their figures are not directly comparable. Both describe a small absolute excess.

The two regulators differ in wording and reach. The EMA called the event a side effect of semaglutide medicines. The FDA calls it a potential increased risk and extends the change to all products in the class, including exenatide, liraglutide, dulaglutide, lixisenatide, tirzepatide and orforglipron (Foundayo), which Pharmacy Times lists as approved in 2026, according to Pharmacy Times’ summary of the notice.

What the notice tells doctors and patients

This part is the regulator’s instruction, not advice from this site. The FDA tells health care professionals to have patients report sudden vision changes in one eye right away, to refer suspected NAION to an ophthalmologist promptly, and to consider discontinuing the drug in patients who develop NAION unless the benefits clearly outweigh the risk.

For patients, the notice says that anyone who has had NAION should talk with a health care professional about whether to continue. It adds that a prior NAION event raises the chance of recurrence, and that NAION in one eye raises the risk in the other. Anyone with questions about their own treatment needs to ask their own prescriber.

Open questions

Nothing in the sources says whether the risk differs by drug, dose, duration or patient group. The FDA found the event reported with all currently marketed GLP-1 drugs, but a class label is not proof that each drug carries the same risk.

The FDA says the underlying cause of NAION is not fully understood, so a causal chain from drug to optic nerve remains unproven. None of the sources I read include a response from the drugmakers.

What happens next is mostly paperwork: label text, then real-world reports under the new wording. Whether the labels produce better detection or just more reports will not be visible for some time.

Sources

  1. U.S. FDA: Drug Safety Communication on GLP-1 receptor agonists and a rare but serious eye condition (9 Nov 2026) fda.gov
  2. European Medicines Agency: PRAC concludes NAION is a very rare side effect of semaglutide medicines ema.europa.eu
  3. Pharmacy Times: FDA requires class-wide GLP-1 RA labeling changes for potential NAION risk pharmacytimes.com